Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

ASCO 2022 Conference Coverage
G

ASCO 2022: A Phase II Study of Gem + Cis Chemo in MIBC With Bladder Preservation for Patients Whose Tumors Harbor Deleterious DNA Damage Response Gene Alterations (Alliance A031701)

By ASCO 2022 Conference Coverage FEATURING Gopa Iyer
By ASCO 2022 Conference Coverage FEATURING Gopa Iyer
131 views
June 8, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

13:36
Exelixis

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Feat. J. Gutierrez, J. Strauss

Featured Video

19:39
Pfizer Hematology

The First Treatment Choice Matters

Feat. A. Ip
Genitourinary
25:32

Multidisciplinary Approaches for Muscle Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

B. Bochner

201 views
29:46

Clinical Perspectives on Managing Hereditary Kidney Cancer

Memorial Sloan Kettering Cancer Center

J. Coleman

53 views
06:55

ASCO® GU 2024 Insights: "HER2 and PD-L1 Immunohistochemistry Express…

Insights from 2024 ASCO® GU Annual Meeting

D. Aggen

112 views
08:56

ESMO 2023 Insights: "MEDI5752 (Volrustomig) in the 1L Treatment of P…

Insights from 2023 ESMO Annual Meeting

M. Voss

132 views
24:28

The Best of GU Radiation Oncology

OncoAlert

S. McBride

278 views
46:48

Theranostics and the Changing Face of Prostate Cancer

University of Colorado Cancer Center

M. Morris

248 views
08:05

ASCO 2022: A Phase II Study of Gem + Cis Chemo in MIBC With Bladder …

ASCO 2022 Conference Coverage

G. Iyer

131 views
44

Lecture Summary - Results of Phase II Clinical Trial of Cabozantinib…

Memorial Sloan Kettering Cancer Center

C. Lee

19 views
07:31

Results of Phase II Clinical Trial of Cabozantinib + Nivolumab for A…

Memorial Sloan Kettering Cancer Center

C. Lee

77 views
06:49

ASCO GU 2022 on Gem & Cis as Neoadjuvant Chemo in High-Grade UTUC: F…

ASCO Genitourinary Cancers Symposium

W. Yip

92 views
06:24

ASCO 2021 Update on mCRPC: VISION Trial Data on Lutetium-177-PSMA-617

ecancer

M. Morris

39 views
04:46
Memorial Sloan Kettering Cancer Center

2020 Update on mRCC: Lenvatinib + Pembro After CPIs: Is There a Bene…

Feat. C. Lee